EA202091505A1 - Триазолазолы циклогексильной кислоты в качестве антагонистов lpa - Google Patents

Триазолазолы циклогексильной кислоты в качестве антагонистов lpa

Info

Publication number
EA202091505A1
EA202091505A1 EA202091505A EA202091505A EA202091505A1 EA 202091505 A1 EA202091505 A1 EA 202091505A1 EA 202091505 A EA202091505 A EA 202091505A EA 202091505 A EA202091505 A EA 202091505A EA 202091505 A1 EA202091505 A1 EA 202091505A1
Authority
EA
Eurasian Patent Office
Prior art keywords
triazolazoles
cyclohexyl acid
lpa antagonists
lpa
antagonists
Prior art date
Application number
EA202091505A
Other languages
English (en)
Russian (ru)
Inventor
Янь Ши
Питер Тай Вах Ченг
Йинь Ван
Джун Ли
Тианан Фэнг
Джеймс Р. Корте
Джун Ши
Хао Чжанг
Лоуренс Дж. Кеннеди
Шивей Тао
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA202091505A1 publication Critical patent/EA202091505A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202091505A 2017-12-19 2018-12-18 Триазолазолы циклогексильной кислоты в качестве антагонистов lpa EA202091505A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607488P 2017-12-19 2017-12-19
PCT/US2018/066123 WO2019126094A1 (en) 2017-12-19 2018-12-18 Cyclohexyl acid triazole azoles as lpa antagonists

Publications (1)

Publication Number Publication Date
EA202091505A1 true EA202091505A1 (ru) 2020-09-22

Family

ID=65003581

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091505A EA202091505A1 (ru) 2017-12-19 2018-12-18 Триазолазолы циклогексильной кислоты в качестве антагонистов lpa

Country Status (16)

Country Link
US (1) US11319315B2 (enExample)
EP (1) EP3728224B1 (enExample)
JP (1) JP7280881B2 (enExample)
KR (1) KR20200100713A (enExample)
CN (1) CN111712492B (enExample)
AR (1) AR113965A1 (enExample)
AU (1) AU2018392325A1 (enExample)
BR (1) BR112020012177A2 (enExample)
CA (1) CA3085938A1 (enExample)
EA (1) EA202091505A1 (enExample)
ES (1) ES2938863T3 (enExample)
IL (1) IL275363A (enExample)
MX (1) MX2020005818A (enExample)
SG (1) SG11202005703TA (enExample)
TW (1) TW201927778A (enExample)
WO (1) WO2019126094A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62710B1 (sr) 2017-12-19 2022-01-31 Bristol Myers Squibb Co Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti
EP3728222B1 (en) * 2017-12-19 2023-03-29 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
US20210379210A1 (en) * 2018-10-15 2021-12-09 Bristol-Myers Squibb Company Radioligands for imaging the lpa1 receptor
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
CN114599641A (zh) 2019-06-18 2022-06-07 百时美施贵宝公司 作为lpa拮抗剂的环丁基羧酸
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
AU2021323515A1 (en) * 2020-08-11 2023-03-09 Viva Star Biosciences Limited Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists
CN116583501A (zh) * 2020-10-22 2023-08-11 罗特斯生物公司 用于治疗与lpa受体活性相关的病症的化合物和组合物
CN114621135B (zh) * 2020-12-11 2024-01-30 上海拓界生物医药科技有限公司 一种lpa1小分子拮抗剂
CN117295717A (zh) 2021-05-11 2023-12-26 吉利德科学公司 Lpa受体拮抗剂及其用途
EP4385988A4 (en) * 2021-08-12 2025-11-05 Shanghai Simr Biotechnology Co Ltd Substituted triazole derivative, its preparation process, pharmaceutical composition thereof and associated use
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
CN115785014B (zh) * 2022-12-27 2025-01-24 瑞石生物医药有限公司 四唑衍生物及其用途
WO2025029733A1 (en) 2023-08-01 2025-02-06 Discovery Energy, Llc Convertible silencer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE447970T1 (de) 2001-02-08 2009-11-15 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
DE102004038403B4 (de) 2004-08-07 2006-08-31 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
JP2011516485A (ja) 2008-04-04 2011-05-26 アイアールエム・リミテッド・ライアビリティ・カンパニー Itpkb阻害剤としての化合物および組成物
WO2011017350A2 (en) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
AU2011338561A1 (en) 2010-12-07 2013-07-25 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
JP5976011B2 (ja) 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US9586963B2 (en) 2011-09-27 2017-03-07 Genfit Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
WO2013070879A1 (en) 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
WO2013085824A1 (en) 2011-12-04 2013-06-13 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
US9187474B2 (en) 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
BR112014030685A2 (pt) 2012-06-20 2017-06-27 Hoffmann La Roche compostos de n-alquiltriazol como antagonistas de lpar
WO2013189865A1 (en) 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-aryltriazole compounds as lpar antagonists
JP6853619B2 (ja) 2015-01-16 2021-03-31 大塚製薬株式会社 シアノトリアゾール化合物の医薬用途
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
RS62710B1 (sr) 2017-12-19 2022-01-31 Bristol Myers Squibb Co Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti

Also Published As

Publication number Publication date
JP7280881B2 (ja) 2023-05-24
IL275363A (en) 2020-07-30
US11319315B2 (en) 2022-05-03
CA3085938A1 (en) 2019-06-27
TW201927778A (zh) 2019-07-16
WO2019126094A1 (en) 2019-06-27
EP3728224B1 (en) 2023-01-11
CN111712492A (zh) 2020-09-25
MX2020005818A (es) 2020-08-20
EP3728224A1 (en) 2020-10-28
US20210163470A1 (en) 2021-06-03
CN111712492B (zh) 2024-05-31
BR112020012177A2 (pt) 2020-11-24
SG11202005703TA (en) 2020-07-29
KR20200100713A (ko) 2020-08-26
AR113965A1 (es) 2020-07-01
JP2021507900A (ja) 2021-02-25
ES2938863T3 (es) 2023-04-17
AU2018392325A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
EA202091500A1 (ru) Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa
MX2020005323A (es) Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
JOP20190174B1 (ar) مثبطات jak1 انتقائية
EA201792519A1 (ru) Противогрибковые соединения
EA201691302A1 (ru) Новые гетероциклические соединения
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
MX377277B (es) Derivados de fenoximetilo.
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
JOP20200030A1 (ar) مركب خماسي الحلقة
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX387920B (es) Peptidos antagonistas de prgc.
EA202091472A1 (ru) Триазол-азины циклогексиловой кислоты как антагонисты lpa